Default company panoramic image

INTICA Biomedical, Inc.

Precision Medicine: Novel Therapeutic & Companion Diagnostic for Triple Negative Breast Cancer (NCI - Contract & Grant Recipient)

  • Stage Product In Development
  • Industry Biotechnology
  • Location Lexington, MA, USA
  • Currency USD
  • Founded March 2011
  • Employees 3
  • Website

Company Summary

INTICA Biomedical, Inc. develops a combination product consisting of Targeted Therapy & Companion Diagnostic for Triple Negative Breast Cancer (TNBC). The novel drug target DEspR and its associated pathway represent true breakthrough discoveries. The NCI and the Susan G Komen Foundation are actively supporting the company's development program in TNBC.


  • Default avatar
    Vicky Herrera

    Professor of Medicine Boston University School of Medicine, Pediatric Cardiology, Molecular Medicine, co-discovery DEspR target, development DEspR-targeted therapy & Diagnostics

  • Default avatar
    Christine Bunt
    President, CEO & Founder

    Christine Bunt is Founder and CEO of INTICA Biomedical, a new life science start-up company, currently still in stealth mode. Prior to INTICA, Christine founded TARIS Biomedical together with Prof. Michael Cima and Prof. Robert Langer from MIT, Cambridge, MA. Previously, Christine was with Merck & Co. for seven years in Whitehouse Station, NJ, where she was leading worldwide commercialization for VIOXX, MAXALT and Cardiovascular Hospital Products

  • Default avatar
    Nelson Ruiz Opazo

    Professor Of Medicine Boston University, Molecular and Cell Biology, co-inventor transgenic rat atherosclerosis model, licensed to Pharmacia through NoMI, co-discovery DEspR target, development DEspR-targeted therapy & Diagnostics

  • Default avatar
    Christopher Horvath
    Vice President of Development

    D.V.M, Lead preclinical development of 5 companies, lead IND & toxicology studies for Millenium Mabs; 6+ MAB/Protein INDs. Lead Development Taligen, Exit preclinical: $ 110 MM

  • Default avatar
    Patrick Wen
    Advisory Board Member/ Dana Faber

    Dr. Wen is Director of Neuro-Oncology at the Dana Faber Cancer Institure in Boston, MA. His research is focused on novel treatments of brain tumors, especially targeted molecular agents. His other clinical interests include neurologic complications of cancer. Dr. Wen is a Professor of Neurology, Harvard Medical School. Dr. Wen currently oversees more than 30 clinical trials in the fields of brain cancer/glioblastoma.

  • Default avatar
    William Li
    Advisory Board Member & Consultant

    Dr. Li is President, Medical Director, and Co-founder of the Angiogenesis Foundation. Dr Li trained in the lab of Dr. Judah Folkman and has been actively engaged in angiogenesis research and clinical development for 22 years

  • Default avatar
    Dennis Ausiello
    Chairman Scientific Advisory Board

    Dr. Ausiello is the Jackson Professor of Clinical Medicine at Harvard Medical School, Chief of Medicine at Massachusetts General Hospital (MGH), and Chief Scientific Officer of Partners Healthcare. Dr. Ausiello serves as the Chairman of the Scientific Advisory Board for INTICA Biomedical.

  • Default avatar
    George Sledge
    Advisory Board Member / ASCO President

    Dr. Sledge currently serves as the Ballve-Lantero Professor of Oncology and Professor of Pathology and Laboratory Medicine at the Indiana University Melvin and Bren Simon Cancer Center. Dr. Sledge is also an active member of the American Association for Cancer Research (AACR) and serves as Chairman of the Breast Cancer Committee, Hoosier Oncology Group.

  • Default avatar
    Sangeeta Bhatia
    Advisory Board Member/ MIT

    Dr. Bhatia is Professor of Health Sciences and Technology and Professor of Electrical Engineering and Computer Science, MIT, Cambridge, Ma. Dr. Bhatia's research in the Laboratory for Multiscale Regenerative Technologies is focused on the applications of micro- and nanotechnology to tissue repair and regeneration. Her research includes a multidisciplinary effort to develop nanomaterials as tools for biological studies and as multifunctional agent


  • Default avatar
    Peter Finn (Corporate), Edward Gates (IP)
    Default avatar
    CFO: Eric Collard

Previous Investors

  • Default avatar
    NIH, NCI, Boston University $3.5 MM +